

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2954596

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BONNIE M. DAVIS	07/22/2014
RECEIVING PARTY DATA	
Name:	SYNAPTEC DEVELOPMENT LLD
Street Address:	P.O. BOX 32743
City:	PALM BEACH GARDENS
State/Country:	FLORIDA
Postal Code:	33420
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6670356
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-708-3467
Email:	ctischler@ladas.com
Correspondent Name:	LADAS & PARRY LLP
Address Line 1:	1040 AVENUE OF THE AMERICAS
Address Line 4:	NEW YORK, NEW YORK 10018
ATTORNEY DOCKET NUMBER:	U 014042-8
NAME OF SUBMITTER:	CRAIG TISCHLER
SIGNATURE:	/Craig Tischler/
DATE SIGNED:	07/25/2014
Total Attachments: 1	
source=014042-86assignment#page1.tif	

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned Bonnie M. Davis (hereinafter as "ASSIGNOR") identified as below hereby sells, assigns, transfers, and sets over to Synaptec Development LLC of P.O. Box 32743, Palm Beach Gardens, Florida, 33420-2743 (hereinafter as "ASSIGNEE"), its successors and assigns, the entire right, title and interest in the patent applications and patents set out in Schedule A hereto and all rights and privileges under any Letters Patent which may be granted thereon, including all rights, if any, to sue for past infringement.

The ASSIGNOR hereby agrees without charge to said ASSIGNEE but at its expense to execute all necessary papers to be used in connection with the above-identified application and any additional, substitute, continuing, divisional, reexamination, or reissue applications, as the ASSIGNEE may deem necessary or expedient; to execute all papers in connection with any interference or other legal or quasi-legal proceedings relating to the above-identified application or any additional, substitute, continuing, divisional, reexamination, reissue applications thereof; to cooperate with the ASSIGNEE in every way possible in obtaining evidence and going forward in any such proceedings; and to perform all other affirmative acts which may be necessary or desirable to obtain a grant of a valid patent for said INVENTION.

The ASSIGNOR hereby agrees to communicate to the ASSIGNEE, or its representatives, any facts known to the ASSIGNOR respecting said INVENTION, and testify in any legal proceedings, sign all lawful papers, execute all necessary assignment papers to cause any and all Letters Patent to be issued to the ASSIGNEE, make all rightful oaths and generally do everything necessary or desirable to aid the ASSIGNEE, its successors and assigns, to obtain and enforce proper protection for said INVENTION.

The ASSIGNOR hereby authorizes and requests the Director of the United States Patent and Trademark Office to issue any and all Letters Patent that may be granted upon any patent application for the INVENTION or any additional, substitute, continuing, or divisional applications thereof to the ASSIGNEE, its successors and assigns.

The ASSIGNOR hereby covenants and warrants that the ASSIGNOR has full right to convey the entire right, title and interest in and to said INVENTION by this assignment, free of any encumbrances and that no other agreement has been or will be executed in conflict herewith.

22 JULY 2014

Date

Bonnie M. Davis

Bonnie M. Davis

126 Via Palacio, Palm Beach Gardens, Florida

Schedule A

US Patent 6150354 issued November 21, 2000, Compounds for treatment of Alzheimer's Disease

US Patent 6670356 issued December 30, 2003, Analogs of galanthamine and lycoramine as modulators of nicotinic receptors

US Patent application 61/969896 filed March 25, 2014, Treatment of Autism

US Patent Application 61/969875 filed March 25, 2014, Parkinson's Treatment

US Patent application 61/994339 filed May 16, 2014, Clearance of Amyloid β